MedTrace Logo

Does Intravitreal Injection of Triamcinolone Acetonide Impairs the Adrenal Function

NCT00561236 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2016-09-08

No results posted yet for this study

Summary

The use of intravitreal corticosteroids in the management ocular inflammatory diseases has recently gained widespread acceptance. The purpose of this study is to determine if the use of intravitreal triamcinolone is associated with suppression of endogenous cortisol production, as generally admitted for patients treated with oral or parenteral corticosteroid therapy.

Conditions

  • Secondary Adrenal Insufficiency

Sponsors & Collaborators

  • HaEmek Medical Center, Israel

    lead OTHER

Principal Investigators

  • Avraham Ishay, MD · Haemek Medical Center , Endocrine Institute

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2007-12-31
Completion
2008-01-31

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00561236 on ClinicalTrials.gov